GERON CORP (GERN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026before open 35 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q4 FY2025Wed, Feb 25, 2026before open 56 8-K
Q3 FY2025Wed, Nov 5, 2025before open 36 8-K
Q2 FY2025Wed, Aug 6, 2025before open 37 8-K
Q1 FY2025Wed, May 7, 2025before open 37 8-K
Q4 FY2024Wed, Feb 26, 2025before open 57 8-K
Q3 FY2024Thu, Nov 7, 2024before open 38 8-K

What they guided beta

Q3 FY2026 "Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights Achieved $60.1 million in RYTELO ® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026 Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the $220 million to $240 million range; lowered 2026 total operating expenses range to $220 million to $230 million Initiated gated commercial launch to expand RYTELO access to eligible LR-MDS patients in targeted European markets, with availability expected in Germany by end of year Ended Q3 2026 with cash, cash " exhibit
Q3 FY2026 "RYTELO is expected to be available in Germany later this year and France in 2027." exhibit
Q3 FY2026 "The decrease was primarily due to lower personnel-related expenses. 2026 Financial Guidance For fiscal year 2026, the Company continues to expect RYTELO net product revenue to be at the mid-to-high end of the $220 million to $240 million range." exhibit
Q3 FY2026 "Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue" exhibit
Q3 FY2026 "These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO’s approved indication; (b) whether the FDA, European Commission and other regulatory authorities will approve imetelstat for other indications with labeling claims that are necessary or desirable for the successful commercialization of RYTELO and without signif" exhibit
Q2 FY2026 "Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Of" exhibit
Q2 FY2026 "Presented the first real-world evidence study of RYTELO in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the European Hematology Association (EHA) 2026 Congress." exhibit
Q2 FY2026 "The increase in research and development expenses was a result of investments in manufacturing and was partially offset by lower headcount costs from the workforce reduction in December 2025." exhibit
Q2 FY2026 "We continue to invest in our RYTELO commercialization strategy while managing lower general and administrative expenses primarily due to a decrease in personnel expense as a result of the workforce reduction in December 2025. 2026 Financial Guidance For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million." exhibit
Q2 FY2026 "Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue range and total operating expense range; (ii) Geron being positioned to build in the future on RYTELO demand and net revenue growth in the second half of 2026; (iii) Geron’s potential European lower-risk MDS commercial strategy for RYTELO; (iv) Geron’s 2026 priorities, including remaining focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/GERN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/GERN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

GERN earnings date badge

HTML

<a href="https://veritasdata.dev/company/GERN/"><img src="https://veritasdata.dev/embed/GERN.svg" alt="GERN earnings date" width="240" height="56"></a>

Markdown

[![GERN earnings date](https://veritasdata.dev/embed/GERN.svg)](https://veritasdata.dev/company/GERN/)

Script

<script async src="https://veritasdata.dev/embed/GERN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/GERN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.